References
- Berry D. J. Gas chromatographic analysis of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (Feprazone) at the therapeutic levels in human plasma. Journal of Chromatography 1975; 114: 159–165
- Berry D. J. Disposition and pharmacokinetics of feprazone in human subjects. Ph.D. thesis, University of Surrey. 1982
- Berry D. J., Parkf D. V. The micro GLC analysis of 4-(3′-3′-dimethylally()-1,2-dipheny(pyrazolidinedione-3,5-dione(Feprazone) in human biosamples. Journal of Pharmaceutical and Biomadical Analysis 1988, accepted
- Bianchi C., Bonardi G. Pharmacological investigation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). Part 3. General pharmacological properties. Arzneimittel-Forschuchung 1972; 22: 196–201
- Cherie-Ligniere G., Colombo B., Carrabba M., Ferrari P., Robotti E. Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis. Arzneimittel-Forschung 1972; 22: 253–258
- Clarke A. J., Clark B., Eason C. T., Parke D. V. An assessment of a toxicological incident in a drug development program and its implications. Regulatory Toxicology and Pharmacology 1985; 5: 109–119
- Dean H. G., Donovan B., Rylett P. The distribution and excretion of C- and H-labelled 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in the rat. Arzneimittel-Forschuchung 1976a; 26: 1574–1581
- Dean H. G., Donovan B., Murray-Leslie G., Rylett P. Absorption and excretion of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in man and dog. Arzneimittel-Forschuchung 1976b; 26: 1700–1704
- Donetti A., Dring L. G., Hiron P. C., William R. T. A study on the metabolism of feprazone utilising mass spectrometry. Mass Spectrometry in Drug Metabolism, A. Frigerio, E. L. Ghisalberti. New York, Plenum 1977; 1–11
- Donetti A., Quintero M. G., Cereda E., Yamaguchi H. Mass spectrometric identification of feprazone metabolites in rat, dog and man. Recent Developments in Mass Spectrometry in Biochemistry and Medicine, A. Frigerio, M. McCamish. Elsevier, Amsterdam 1980; Vol. 6: 203–215
- Fumagalli G., Mazzola C., Chierichetti S. Clinical and laboratory studies of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in bronchopulmonary diseases. Arzneimittel-Forschuchung 1972; 22: 274–278
- Gaetani M., Debeus R., Bonardi G., Coppi G. Toxicological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). Part 1. Subacute and chronic toxicity in rats and dogs. Arzneimittel-Forschuchung 1972; 22: 216–223
- Gaetani M., Yamaguchi H., Vidi A., Hashimoto Y., Donetti A. Species differences in the metabolism of feprazone, an anti-inflammatory drug. Pharmacology Research Communications 1979; 11: 719–730
- Haer F. C. An Introduction to Chromatography on Impregnated Glass Fibre. Arbor-Humphrey, London 1970
- Idle J. R., Mahgoub A., Lancaster R., Smith R. L. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sciences 1978; 22: 979–983
- Morton D. M., Chatfield D. M. The effect of adjuvant-induced arthritis in the liver metabolism of drugs in rats. Biochemical Pharmacology 1970; 19: 473–481
- Pala G., Mantegani A., Donetti A., Lumachi B., Marazzi-Uberti E., Casadio S. Structure-activity relationships in anti-inflammatory compounds chemically related to 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). Arzneimittel-Forschuchung 1972; 22: 174–177
- Parke D. V. Adverse effects of drugs. Journal of the Royal Society of Health 1985; 105: 39–46
- Toft P., Dring L. G., Hiron P. C., Williams R. T., Donetti A., Midgley J. M. The metabolism of 14C-prenazone in the rat. Xenobiotica 1975; 5: 729–739
- Weber J. C. P. Epidemiology of adverse reactions to non-steroidal antiinflammatory drugs. Advances in Inflammation Research, K. D. Rainsford, G. P. Velo. Raven, New York 1984; Vol. 6: 1–7
- Yamaguchi H., Kubo J., Sekine K., Naruchi T., Hashimoto Y., Kato R. Metabolites of feprazone in man. Drug Metabolism and Disposition 1979; 7: 340–344